<DOC>
	<DOCNO>NCT00783289</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability escalate multiple SC dose MEDI-563 adult subject asthma .</brief_summary>
	<brief_title>A Phase 2a Study Evaluate Safety Tolerability MEDI-563 Adults With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Male female subject . Age 18 80 year screen . Written inform consent HIPAA authorization obtain subject prior performing protocolrelated procedure , include screen evaluation . Previously document diagnosis asthma ≥ 1 year duration , base episodic symptom airflow obstruction ; postbronchodilator reversibility airflow obstruction ≥ 12 % ( screen document within 1 year prior randomization ) ; proof positive response methacholine challenge ( document within 1 year prior randomization ) represent provoke concentration methacholine cause 20 % fall force expiratory volume 1 second ( FEV1 ) ; ( PC20 ) &lt; 8 mg/mL . Weight ≥ 45 kg ≤ 135 kg ( ≥ 100 lbs ≤ 300 lb ) . Able produce spirometry reading meet ATS/European Respiratory Society ( ERS ) standard . Screening prebronchodilator FEV1 ≥ 60 % . Women childbearing potential , unless surgically sterile ( include tubal ligation ) and/or least 2 year postmenopausal , must use 2 effective method avoid pregnancy ( include oral , transdermal , implanted contraceptive , intrauterine device , female condom spermicide , diaphragm spermicide , cervical cap , abstinence , use condom spermicide sexual partner , sterile sexual partner ) 14 day prior first dose investigational product Study Day 0 , must agree continue use precaution Study Day 161 . Cessation birth control point discuss responsible physician . Men , unless surgically sterile , must likewise use 2 effective method birth control ( eg , condom spermicide ) must agree continue use contraceptive precaution End Study/Study Day 161 . Ability complete study period , include followup period Study Day 161 require protocol . Previously receive MEDI563 . History allergy reaction component investigational product formulation . History allergy reaction market experimental monoclonal antibody therapy , intravenous gammaglobulin ( IVIG ) , blood product . Receipt investigational drug therapy within 30 day prior randomization study biologic ( ) within 5 half life agent prior randomization study . Treatment oral systemic burst corticosteroid within 4 week prior randomization study . Use chronic systemic immunosuppressive drug , include oral corticosteroid within 4 week prior randomization study . Current use oral ophthalmic βadrenergic antagonist ( eg , propranolol ) , must stop 2 week prior randomization study . Current allergy vaccination ( immunotherapy ) . History anaphylaxis . Lung disease persistent asthma [ eg , chronic bronchitis , cystic fibrosis , chronic obstructive pulmonary disease ( COPD ) , tuberculosis ( TB ) ] . Acute illnesses evidence significant active infection , fever ≥ 38.0°C ( ≥ 100.5°F ) screening time first dose investigational product . History ingestion untreated water location know infected parasite , result acute chronic diarrhea ; untreated parasitic infection within 1 month randomization . Pregnancy ( woman childbearing potential must negative serum pregnancy test screen negative urine pregnancy test prior administration investigational product ) . Lactating woman . Infection HIV1 , HIV2 , hepatitis A , B , C virus . History cancer , apart basal cell carcinoma situ carcinoma cervix treat apparent success curative therapy ≥ 1 year prior randomization study . History cigarette smoking ≥ 10 pack year . History alcohol abuse drug abuse require treatment &lt; 1 year prior randomization study . Elective surgery plan study period . Evidence systemic disease find upon physical examination , laboratory abnormality , CXR , ECG , opinion investigator medical monitor , may compromise safety subject study confound analysis study result . Employees clinical study site individual involve conduct study , first degree family member individual ( ie , parent , sibling , child ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>